As a model antibody for investigation of the Ab-GNP platforms, we used cetuximab, a clinically employed monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR), which is overexpressed in many human cancers.40–42 Binding of the antibody to EGFR blocks activation of multiple kinases and leads to subsequent tumor cell growth inhibition and apoptosis.40–42 Our results show a relationship between the different synthesis parameters and Ab-GNP functionality. Here, EGFR is linked to neoplasm.